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 Diabetic retinopathy (DR) is the major cause of visual impairment in the 
working-age population with type 2 diabetes mellitus (T2DM). Magnesium 
(Mg) is involved in various metabolic processes and in experimental animal 
studies; Mg has shown essential roles in physiological eye function. 
Magnesium deficiency is common in T2DM; therefore we analyzed the 
association between serum Mg status and the presence of DR in T2DM 
patients. Systematic literature searching in several databases, from 1988 to 
September 2020, was performed using search terms: “serum magnesium” or 
“hypomagnesemia” and “diabetic retinopathy” or “retinopathy”. A total of 
3,227 patients from 17 studies were included in this meta-analysis. 
Hypomagnesemia was associated with increased risk of developing DR (OR 
4.52 [2.08, 9.81], p=0.0001) in T2DM patients. Serum Mg levels also lower 
in patients with DR than those without DR (MD –0.30 mg/dL [–0.44, –0.15], 
p<0.0001). Additionally, serum Mg levels were lower in patients with 
proliferative DR (PDR) than those with non-proliferative DR (NPDR) (MD-
0.21 mg/dL [–0.34, –0.09], p=0.0009). Leave-one-out sensitivity analysis did 
not change the overall effect. Hypomagnesemia or low serum Mg levels in 





Type 2 diabetes mellitus 
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1. INTRODUCTION  
Diabetes mellitus (DM) is a major public health problem, affecting over 300 million individuals 
worldwide, and T2DM is estimated to be 95% of all diagnosed cases [1], [2]. Multi-system long term 
complications of T2DM also had significant morbidity and affect the quality of life in these patients. Diabetic 
retinopathy is a highly specific neurovascular complication of diabetes and is the most common cause of 
visual impairment in the working-age population [3]-[5]. The prevalence of DR from previous study was 
35% in people with DM and 10% already in vision-threatening stages [3]. The incidence of blindness may be 
reduced up to 90% with the current surgical and medical techniques. The pathogenesis of DR involved a 
complex biochemical mechanism associated with hyperglycemia. These include oxidative stress, and 
advanced glycation end-products (AGEs) formation [6]. However, the link between hyperglycemia and 
retinal vascular lesions remains unclear; also several therapeutic agents targeted those biochemical pathways 
have yet to show promising results [7]. 
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Magnesium is the fourth most common cation in the body and the second most common 
intracellular cation [8]. Magnesium is essential in many fundamental biochemical processes, including 
energy metabolism and nucleic acid synthesis. Deficiency of Mg is fairly common and multifactorial [9]. The 
prevalence of Mg deficiency in DM patients is estimated to be 25-39%. Although the exact mechanism of 
Mg deficiency in patients with diabetes is not completely understood, osmotic diuresis contributes for 
majority of the Mg loss. Glucosuria in the diabetic state impairs renal tubular reabsorption of Mg from the 
glomerular filtrate. Hypomagnesemia, in turn, might worsen glycemic control in T2DM patients, as it is 
involved in insulin secretion, binding, and activity [8], [10]-[12]. 
Although the relationship between serum Mg and insulin resistance is well documented, the 
association between serum Mg and diabetic complications, especially DR, are still unclear [13]-[16]. In 
experimental animal studies, Mg has shown essential roles in eye development and physiological function 
[17], [18]. Several observational studies have explored the association between serum Mg and DR. A 
systematic review also has been conducted to investigate the association between micronutrients, including 
Mg, and DR [16]. However, to our knowledge, there is no meta-analysis evaluating the association between 
the two yet. Therefore, our present study intended to evaluate the association between serum Mg status and 
the presence of DR in T2DM patients.  
 
 
2. RESEARCH METHOD 
This meta-analysis was carried out according to Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement. 
 
2.1.  Eligibility criteria 
All articles in adult T2DM patients evaluating the association between serum Mg and DR with 
information regarding serum Mg status or levels, and the presence of DR as outcome were included in this 
meta-analysis. Articles such as: case report or case series, review articles, letters to editor, editorial or 
commentaries, animal studies, and non-English articles were excluded. 
 
2.2.  Database search and study selection 
We searched the PubMed, EuropePMC, ScienceDirect, Cochrane Central databases and Google 
Scholar from 1988 to September 2020 using search terms: “serum magnesium” or “hypomagnesemia” and 
“diabetic retinopathy” or “retinopathy”. Full text of all articles including the cross references related to our 
topics were retrieved; duplicates then removed. Authors (R.P.A, R.D.A) then screened the articles 
independently by its abstracts for relevance. The articles were thoroughly reviewed and only those which met 
the eligibility criteria were analyzed. Dispute among investigators was resolved through discussion and 
consultation with the senior investigator (J.H.P). 
 
2.3.  Data extraction 
Data from included studies were extracted independently using a piloted data extraction form by two 
authors (R.P.A, R.D.A). The data extraction form included the authors’ last name, year of the study, study 
location, study design, sample size, serum Mg assay method, the prevalence of hypomagnesemia, serum Mg 
levels, number of cases with DR, and PDR/NPDR (if present). Hypomagnesemia was defined according to 
the study reference value respectively, which cut-off value ranging from 1.5-1.8 mg/dL. Serum Mg levels 
means and SDs was presented in mg/dL and measurements in mmol/L were converted to mg/dL. 
 
2.4.  Study quality 
The quality of the study was assessed using modified newcastle-ottawa scale (NOS) [19], [20]. The 
modified NOS encompass 3 domains: selection of participants, comparability of the participant group, and 
exposure ascertainment, comprises of total 10 items with 10 is the maximum score. A score of ≥7 was 
considered to be a high-quality study. Two investigators (R.P.A, R.D.A) assessed the quality of the studies 
selected independently. 
 
2.5.  Statistical analysis 
Meta-analysis was performed using Review Manager 5.4 (The Cochrane Collaboration, 2020) and 
comprehensive meta analysis (CMA) program version 3. Mantel-Haenszel formula was used to calculate 
dichotomus variables. Continuous variables were calculated using inverse-variance method. Random effects 
models were used despite the heterogeneity. Odds ratios (ORs) and mean differences (MDs) were reported 
with 95% confidence intervals (CIs). The p-value was two tailed and statistical significance of ≤0.05 was 
used. 
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Statistical heterogeneity was calculated with the I
2
 test and the Q-statistic test. I
2
 test >50% indicated 
substantial heterogeneity across the studies. Leave-one-out analysis also performed to assess how each 
individual study affects the overall estimate of the rest of the studies should significant heterogeneity present. 
In addition, subgroup analysis was performed to explore other causes of heterogeneity. Funnel plot was used 
to assess for publication bias; an asymmetrical shape indicates publication bias. The regression-based Egger’s 
test was performed to assess small-study effect.  
 
 
3. RESULTS AND DISCUSSION 
3.1.   Results 
3.1.1. Study characteristics and selection 
We found a total of 547 records, and after duplicates were removed, 469 records remained. After 
thoroughly screening and evaluating the abstracts, 27 studies were included for full-text article assessment. 
However, five studies did not define the type of diabetes included and four studies presented unusable 
statistical data; thus they were excluded from this present study. Eighteen studies were included for 
methodological quality assessment according to modified NOS. One study scored below 7 and then excluded 
Figure 1. The average modified NOS of the studies included in this meta-analysis were 7.82 and only high 
quality studies were included (supplementary Table S1 and S2). The characteristics of the included studies 





Figure 1. PRISMA flow diagram 
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There were a total of 3,227 patients from 17 studies, among which 13 studies conducted in India. All 
the studies included were observational in design, either cross-sectional or case-control. Three different assay 
methods were used to measure serum Mg levels. The diagnosis of DR were based on primary data from eye 
examinations, interview, or through medical records for history of DR treatments. Eight studies reported the 
association of hypomagnesemia and the presence/absence of DR [21]-[28]. Seven studies reported the 
comparison of serum magnesium levels in the group of subjects with DR and without DR [29]-[35]. Two 
studies reported both informations in the full-text articles [36], [37]. 
 
 




3.1.2.  Hypomagnesemia and diabetic retinopathy 
This present study showed that hypomagnesemia was associated with increased risk of developing 
DR (OR 4.52 [2.08, 9.81], p=0.0001), although significant heterogeneity was observed (I
2
: 90%, p< 0.00001) 
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3.1.3. Serum magnesium levels and diabetic retinopathy 
Serum Mg levels were lower in patients with DR than those without DR (MD –0.30 mg/dL [–0.44, –
0.15], p<0.0001) despite the presence of significant heterogeneity (I
2
: 94%, p<0.00001) as represented in 
Figure 3. Additionally, serum Mg levels were lower in patients with PDR than those with NPDR (MD –0.21 
mg/dL [–0.34, –0.09], p=0.0009; I
2





Figure 3. Magnesium levels in diabetic retinopathy and non-diabetic retinopathy. Lower serum Mg levels 





Figure 4. Magnesium levels in proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. 
Lower serum Mg levels were associated with proliferative diabetic retinopathy 
 
 
3.1.4. Sensitivity and subgroup analysis 
Sensitivity analysis by leave-one-out was performed to single out the potential sources of 
heterogeneity in this study. In the result of the pooled OR, after excluding the study by Hyassat et al. [22] the 
heterogeneity was reduced to 72% (OR 5.53 [3.08, 9.94], p<0.00001). Further exclusion of any other single 
study did not significantly alter the pooled OR and heterogeneity. In the comparison of serum Mg levels MDs 
between group with and without DR, excluding the study by Navin et al. [35] slightly reduced the 
heterogeneity to 90% (MD –0.24 mg/dL [–0.36, –0.12], p=0.0001). Exclusion of any other single study did 
not significantly alter the overall MD and heterogeneity. 
In subgroup analysis of study design, there were greater heterogeneities in cross-sectional study 
design (I
2
: 93%, p<0.00001) compared to case-control (I
2
: 0%, p = 0.74) for the pooled OR (supplementary 
materials figure S1). Meanwhile, obvious heterogeneities were observed in both cross-sectional (I
2
: 83%, 
p=0.0005) and case-control (I
2
: 96%, p<0.00001) study design for the overall MD result (supplementary 
materials figure S2). In the subgroup of serum Mg assay methods, the heterogeneities were higher with 
photometric methods (I
2
: 92%, p<0.00001) than with enzymatic method (I
2
: 0%, p=0.87) for the pooled OR 
(supplementary materials figure S3). For the overall MD, obvious heterogeneities were observed in both 
photometric (I
2
: 94%, p<0.00001) and atomic absorption (I
2
: 97%, p<0.00001) methods (supplementary 
materials Figure S4). 
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3.1.5. Publication bias 
Funnel-plot showed asymmetrical shape for both pooled OR and serum Mg levels MD Figure 5, 
indicating possible publication bias. However, Egger’s test only showed small-study effects for serum Mg 





Figure 5. Funnel-plot analysis; (A) Asymmetrical funnel plots for hypomagnesemia in diabetic retinopathy 




Magnesium as the fourth most common cation in the body was largely ignored up until recently. In 
recent years, the role of Mg in many fundamental biochemical and physiological processes has gained large 
interest. Magnesium is involved in: hormone receptor action, transmembrane ion transport, neuron activity, 
cardiac excitability, and vascular tone [38]. Changes in intracellular or extracellular Mg concentration may 
affect cell function through its effect on calcium handling. Due to its strong binding with Adenosine 
triphosphate (ATP) molecules, the majority of intracellular Mg is located within mitochondria. Metabolically 
active cell generally has higher intracellular Mg content. Meanwhile, plasma Mg levels of healthy people are 
maintained within narrow range of 1.7-2.4 mg/dL (0.7-1.0 mmol/L) [8], [39], [40].  
Hypomagnesemia typically defined as having serum Mg levels below 1.6 mg/dL, but it is commonly 
under diagnosed [41]. It might result from one or more of the following: reduced intake, impaired intestinal 
absorption, redistribution, increased gastrointestinal from diarrhea or renal loss. Thus it is recommended that 
Mg levels should be measured routinely in patients with conditions, diseases or treatment that may 
predispose to Mg deficiency [42]. Magnesium deficiency is prevalent in T2DM patients. Glucosuria impairs 
renal tubular reabsorption of Mg and accounts for a portion of the Mg loss [8], [41], [43]. Considering the 
various etiology of hypomagnesemia, the studies included in this meta-analysis must controlled for important 
confounders as: drugs known to affect Mg levels, presence of acute or chronic diarrheal/malabsorption states, 
taking supplements containing Mg, alcoholics, and presence of other endocrine disorders. 
Diabetes duration, poor glycemic control, nephropathy, hypertension, and dyslipidemia were 
established as modifiable risk factors for DR [5]. Magnesium deficiency is suggested as a possible novel risk 
factor for DR for the following reasons: i) Mg serves a fundamental role in energy metabolism, ii) retina is 
the most metabolically active tissue in the body, hence sensitive to hypoxia, iii) Mg has a vital role in the 
development and physiological eye function in experimental animal studies [7], [8], [18], [34]. The main 
result of our present meta-analysis provided evidence that hypomagnesemia and low Mg levels in T2DM 
patients increased the risk of developing DR (OR 4.52 [2.08, 9.81], p=0.0001; MD –0.30 mg/dL [–0.44, –
0.15], p<0.0001). The association between hypomagnesemia and DR remained significant in subgroup 
analysis of the study design and the serum Mg measurement method used. These findings were different with 
the study by Hyassat et al. [22] however, the non-significant result might be due to a higher proportion of 
subjects with poor glycemic control in group with normal Mg level. 
The pathogenesis of DR is related to structural and functional changes in retinal vasculature [4], 
[44]. Although the mechanism of hypomagnesemia induced microangiopathy still unclear, evidences 
indicated that Mg deficiency sensitize vascular smooth muscle to various vasospasm inducing neuro-
hormonal substances [45]. Magnesium deficiency also increases production of thromboxane A2, endothelin-
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1, and reduces prostacyclin production. Study of oral Mg supplementation in diabetic patients was shown to 
improve endothelial functions through increased nitric oxide (NO) production and induced vasorelaxation 
[46]. As retinal ischemia progresses, the vascular occlusion will induce expression of vascular endothelial 
growth factor (VEGF) which resulting in reactive retinal vascular proliferation [47], [48]. The latter is a 
marker of a more advanced form of DR, known as proliferative diabetic retinopathy. It is consistent with the 
result of the present meta-analysis which serum Mg levels were lower in patients with PDR than those with 
NPDR (MD –0.21 mg/dL [–0.34, –0.09], p=0.0009). 
Vascular dysfunction and repeated reperfusion injury will lead to increased oxidative stress and 
glutamate retention in retinal tissue [49]. The glutamate-induced excitotoxicity in neuronal tissues is 
mediated through N-methyl-D-aspartate (NMDA) receptors which are coupled with voltage-gated calcium 
channels [50]. Being primarily regarded as calcium antagonist, in Mg deficiency, excessive calcium ions 
influx through NMDA receptors will take place. Calcium accumulation causes cellular swelling and cell 
death. Furthermore, excess calcium influx also causes oxidative stress with the generation of neurotoxic free 
radicals. In the presence of Mg deficiency, reduced activity of superoxide dismutase will lead to lipid 
peroxidation of Polyunsaturated fatty acids (PUFA) rich membranes by free radicals and impairs retinal 
function [18], [40], [47].  
The main strength of this study is the strong evidence of the relationship between hypomagnesemia 
or low serum Mg levels in T2DM patients and increased risk of developing DR. However, our study has 
several limitations. First, the presence of publication bias which most of the studies are from India. Second, 
the studies included were observational by nature and mostly cross-sectional in design. Third, although the 
authors have made extensive efforts to ensure that all studies included controlling for the most important 
confounders (factors that might affect serum Mg levels); there were still diverse additional confounding 
factors across the studies (age, presence of microalbuminuria-nephropathy, diabetes treatments, diet). Lastly, 




This present meta-analysis indicates relationship between hypomagnesemia or low serum Mg levels 
in T2DM patients and increased risk of developing diabetic retinopathy (DR). Magnesium deficiency will 
induce microangiopathy and excitotoxicity in retinal tissue. Still, further studies with other study design 
(prospective, retrospective cohort) are required; moreover randomized controlled trials to determine the 
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